News
Milvexian is in three late-stage studies in AF, stroke, and acute coronary syndromes (ACS), while abelacimab is in the phase 3 LILAC-TIMI 76 in patients with AF deemed unsuitable for current OAC ...
Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...
Abelacimab is a fully human monoclonal antibody that binds to the catalytic domain of the inactive form of FXI and prevents the generation of the activated form (FXIa). 13 The AZALEA-TIMI 71 trial ...
The investigational antibody targets Factor XI, a key clotting protein. In 2019, Novartis helped launch Anthos alongside Blackstone Life Sciences, in the process offloading abelacimab to the startup.
Anthos Therapeutics, Inc., a formation of Blackstone (NYSE: BX) Life Sciences and Novartis AG (NYSE: NVS), is a clinical-stage biopharmaceutical company developing and commercializing innovative ...
GSK Licenses Shigella Vaccine altSonflex1-2-3 to Bharat Biotech: Strategic licensing agreement advances late-stage development and expands potential vaccine access in low- and middle-income countries.
Nordic Capital acquired a majority stake in health data platform Arcadia. Together, the two aim to accelerate the company’s mission of advancing value-based care through AI and data analytics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results